Background Non-metastatic castration-resistant prostate cancer (nmCRPC) patients are often older and use concurrent medications that increase potential for drug-drug interactions (pDDIs). This study assessed pDDI prevalence in real-world nmCRPC patients treated with apalutamide, darolutamide, or enzalutamide.
No takes yet. Share an insight, caveat, or question.
Appukkuttan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: